High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers

Journal of the National Cancer Institute

Volumn 100, Issue 1, 2008, Pages 48-58

  Bollet, Marc A ^a   Servant, Nicolas ^a   Neuvial, Pierre ^a   Decraene, Charles ^a,b   Lebigot, Ingrid ^a   Meyniel, Jean Philippe ^a   De Rycke, Yann ^a   Savignoni, Alexia ^a   Rigaill, Guillem ^a   Hupé, Philippe ^a,b   Fourquet, Alain ^a   Sigal Zafrani, Brigitte ^a   Barillot, Emmanuel ^a   Thiery, Jean Paul ^a,c  

^a INSTITUT CURIE   (France)

^b CNRS   (France)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLUSTER ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENE MAPPING; HISTOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; BREAST TUMOR; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; DNA STRAND BREAKAGE; FEMALE; GENETICS; LUNG CARCINOMA; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; SECOND CANCER; TUMOR RECURRENCE;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; DNA BREAKS; DNA, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH DESIGN;

EID: 38049110961     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm266     Document Type: Article

References (61)

1. Temple WJ, Russell ML, Parsons LL, et al. Conservation surgery for breast cancer as the preferred choice: a prospective analysis. J Clin Oncol. 2006;24(21):3367-3373.
2. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087-2106.
3. Engel J, Kerr J, Schlesinger-Raab A, Sauer H, Holzel D. Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study. Breast J. 2004;10(3):223-231.
4. Moyer A. Psychosocial outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. Health Psychol. 1997;16(3):284-298.
5. Haffty BG, Carter D, Flynn SD, et al. Local recurrence versus new primary: clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol Biol Phys. 1993;27(3):575-583.
6. Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002;95(10):2059-2067.
7. Gage I, Recht A, Gelman R, et al. Long-term outcome following breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1995;33(2):245-251.
8. Touboul E, Buffat L, Belkacemi Y, et al. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys. 1999;43(1):25-38.
9. Recht A, Silen W, Schnitt SJ, et al. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1988;15(2):255-261.
10. Komoike Y, Akiyama F, Iino Y, et al. Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer. 2005;12(2):104-111.
11. Smith TE, Lee D, Turner BC, Carter D, Haffty BG. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000;48(5):1281-1289.
12. Schlechter BL, Yang Q, Larson PS, et al. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol. 2004;22(10):1830-1838.
13. Wang ZC, Buraimoh A, Iglehart JD, Richardson AL. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays. Breast Cancer Res Treat. 2006;97(3):301-309.
14. Vicini FA, Antonucci JV, Goldstein N, et al. The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy. Cancer. 2007;109(7):1264-1272.
15. van der Sijp JR, van Meerbeeck JP, Maat AP, et al. Determination of the molecular relationship between multiple tumors within one patient is of clinical importance. J Clin Oncol. 2002;20(4):1105-1114.
16. Shibata A, Tsai YC, Press MF, Henderson BE, Jones PA, Ross RK. Clonal analysis of bilateral breast cancer. Clin Cancer Res. 1996;2(4):743-748.
17. Kuukasjarvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997;57(8):1597-1604.
18. Waldman FM, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Ljung BM. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst. 2000;92(4):313-320.
19. Teixeira MR, Ribeiro FR, Torres L, et al. Assessment of clonal relationships in ipsilateral and bilateral multiple breast carcinomas by comparative genomic hybridisation and hierarchical clustering analysis. Br J Cancer. 2004;91(4 ):775-782.
20. Zhao X, Li C, Paez JG, et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 2004;64(9):3060-3071.
21. Balaton AL, Coindre JM, Collin F, et al. Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of Centres to Combat Cancer/French Association for Quality Assurance in Pathology. Ann Pathol. 1996;16:144-148.
22. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23-28.
23. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press;1989.
24. Hupe P, La Rosa P, Liva S, Lair S, Servant N, Barillot E. ACTuDB, a new database for the integrated analysis of array-CGH and clinical data for tumors. Oncogene. 2007;26:6641-6652.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
26. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman & Hall; 1984.
27. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics. 2004;20(18):3413-3422.
28. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006;444(7118):444-454.
29. La Rosa P, Viara E, Hupe P, et al. VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics. 2006;22(17):2066-2073.
30. Dice LR. Measures of the amount of ecologic association between species. Ecology. 1945;26:297-302.
31. Ward JH. Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 1963;58:236-244.
32. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73(3):643-651.
33. Sobin LH, Wittekind C. TNM classification of malignant tumours. New York: Wiley-Liss; 2002.
34. Vrieling C, Collette L, Fourquet A, et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. Eur J Cancer. 2003;39(7):932-944.
35. Fourquet A, Campana F, Zafrani B, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys. 1989;17(4):719-725.
36. Borger J, Kemperman H, Hart A, Peterse H, van Dongen J, Bartelink H. Risk factors in breast-conservation therapy. J Clin Oncol. 1994;12(4):653-660.
37. Elkhuizen PH, van de Vijver MJ, Hermans J, Zonderland HM, van de Velde CJ, Leer JW. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys. 1998;40(4):859-867.
38. Elkhuizen PH, Voogd AC, van den Broek LC, et al. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys. 1999;45(1):73-83.
39. Oh JL, Bonnen M, Outlaw ED, et al. The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: how young is "young"?. Int J Radiat Oncol Biol Phys. 2006;65(5):1345-1352.
40. Bollet MA, Sigal-Zafrani B, Mazeau V, et al. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young(<40 years) women treated with breast conserving surgery first. Radiother Oncol. 2007;82(3):272-280.
41. Li G, Robinson GW, Lesche R, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development. 2002;129(17):4159-4170.
42. Sapolsky RJ, Hsie L, Berno A, Ghandour G, Mittmann M, Fan JB. High-throughput polymorphism screening and genotyping with high-density oligonucleotide arrays. Genet Anal. 1999;14(5-6 ):187-192.
43. Jonsson G, Staaf J, Olsson E, et al. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer. 2007;46(6):543-558.
44. Perez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res. 2007;13(12):3577-3584.
45. Chen LC, Kurisu W, Ljung BM, Goldman ES, Moore D 2nd, Smith HS. Heterogeneity for allelic loss in human breast cancer. J Natl Cancer Inst. 1992;84(7):506-510.
46. Lininger RA, Fujii H, Man YG, Gabrielson E, Tavassoli FA. Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast. Mod Pathol. 1998;11(12):1151-1159.
47. Sigal-Zafrani B, Bollet MA, Antoni G, et al. Are ipsilateral breast tumour invasive recurrences in young(40 years) women more aggressive than their primary tumours?. Br J Cancer. 2007;97(8):1046-1052.
48. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99(4):283-290.
49. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272-282.
50. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99(9):727-737.
51. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427-437.
52. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23(33):8469-8476.
53. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356(13):1295-1303.
54. Kreike B, Halfwerk H, Kristel P, et al. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res. 2006;12(19):5705-5712.
55. Nuyten DS, Kreike B, Hart AA, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006;8(5):R62.
56. Niméus E, Krogh M, Malmström P, Strand C, Fredriksson I, Karlsson P, et al. Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence despite postoperative radiotherapy after breast conserving surgery. In: 29th Annual San Antonio Breast Cancer Symposium 2006. San Antonio, TX: 2007;103(1):115-124.
57. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol. 1994;145(6):1301-1308.
58. Devries S, Nyante S, Korkola J, et al. Array-based comparative genomic hybridization from formalin-fixed, paraffin-embedded breast tumors. J Mol Diagn. 2005;7(1):65-71.
59. Johnson NA, Hamoudi RA, Ichimura K, et al. Application of array CGH on archival formalin-fixed paraffin-embedded tissues includ ing small numbers of microdissected cells. Lab Invest. 2006;86(9):968-978.
60. Oosting J, Lips EH, van Eijk R, et al. High-resolution copy number analysis of paraffin-embedded archival tissue using SNP BeadArrays. Genome Res. 2007;17(3):368-376.
61. Schubert EL, Hsu L, Cousens LA, et al. Single nucleotide polymorphism array analysis of flow-sorted epithelial cells from frozen versus fixed tissues for whole genome analysis of allelic loss in breast cancer. Am J Pathol. 2002;160(1):73-79.